Kimiskidis V K, Papadakis E, Papaliagkas V, Papagiannopoulos S, Galanakis D K
Laboratory of Clinical Neurophysiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Hematology Dept-Hemostasis Unit, Papageorgiou General Hospital, Thessaloniki, Greece.
Hippokratia. 2017 Jan-Mar;21(1):49-51.
The inherited dysfibrinogenemias comprise rare congenital coagulation disorders which are clinically characterized by bleeding diathesis and, in occasional patients, by thrombotic tendency or combined bleeding-thrombotic events. In recent years, accumulating evidence suggested that fibrinogen has a critical role in the pathogenesis of neuroinflammatory disorders, including multiple sclerosis. We describe the presentation and long-term follow-up of a patient with inherited dysfibrinogenemia and concomitant clinical and laboratory evidence of demyelinating disease. Case description: A 16-year-old male patient presented in 2003 with bilateral sensory symptomatology preceded by an episode of epistaxis. His past medical history included episodes of spontaneous nosebleeds as well as Duane syndrome and mild atrophy of the right upper limb. Coagulation testing of the patient and his asymptomatic father revealed in both the presence of a clotting defect, consistent with inherited dysfibrinogenemia (named Fibrinogen Thessaloniki). Within seven months, the patient presented with a new episode of motor semiology whereas serial brain magnetic resonance imaging (MRI) scans revealed T2 lesions with bilateral distribution, some of which with gadolinium enhancement. The cerebrospinal fluid examination disclosed the presence of oligoclonal bands in the central nervous system compartment. The patient was started on azathioprine (2.5 mg/kg/24h) which led to clinical and radiological stabilization for nine years. In 2013, the dose of azathioprine was reduced, due to an elevation of his amylase levels, resulting in radiological deterioration with an increased T2 lesion load. The reinstitution of azathioprine at therapeutic doses led to radiological improvement and clinical stability as of today.
The described case of inherited dysfibrinogenemia and concomitant multiple sclerosis provides speculative evidence for a causal link, rather than a chance association, between these two entities. Further studies are warranted to corroborate this hypothesis in experimental and clinical settings. HIPPOKRATIA 2017, 21(1): 49-51.
遗传性异常纤维蛋白原血症是罕见的先天性凝血障碍,临床特征为出血倾向,部分患者还伴有血栓形成倾向或出血 - 血栓形成联合事件。近年来,越来越多的证据表明纤维蛋白原在包括多发性硬化症在内的神经炎症性疾病的发病机制中起关键作用。我们描述了一名患有遗传性异常纤维蛋白原血症且伴有脱髓鞘疾病临床和实验室证据患者的临床表现及长期随访情况。
一名16岁男性患者于2003年出现双侧感觉症状,之前有鼻出血发作史。他的既往病史包括自发性鼻出血、杜安综合征以及右上肢轻度萎缩。对该患者及其无症状父亲进行的凝血检测显示两人均存在凝血缺陷,符合遗传性异常纤维蛋白原血症(命名为纤维蛋白原塞萨洛尼基)。在七个月内,患者出现了新的运动症状发作,而系列脑磁共振成像(MRI)扫描显示双侧分布的T2病变,其中一些有钆增强。脑脊液检查显示中枢神经系统存在寡克隆带。患者开始使用硫唑嘌呤(2.5mg/kg/24小时),临床和影像学稳定了九年。2013年,由于淀粉酶水平升高,硫唑嘌呤剂量减少,导致影像学恶化,T2病变负荷增加。恢复治疗剂量的硫唑嘌呤后,至今影像学改善且临床稳定。
所描述的遗传性异常纤维蛋白原血症合并多发性硬化症病例为这两种疾病之间的因果关系而非偶然关联提供了推测性证据。需要进一步研究在实验和临床环境中证实这一假设。《希波克拉底》2017年,21(1): 49 - 51。